Acadia Pharmaceuticals ACAD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.1B+2.2% | $1.07B+2.3% | $1.05B+2.8% | $1.02B+2.3% | $996.28M+4.0% | ||
| $93.4M+4.9% | $89M+5.2% | $84.58M+3.4% | $81.79M+3.2% | $79.28M-3.1% | ||
| $1B+2.0% | $982.51M+2.1% | $962.54M+2.7% | $937.1M+2.2% | $917M+4.7% | ||
| 91.5%-0.2pp | 91.7%-0.2pp | 91.9%-0.1pp | 92%-0.1pp | 92%+0.6pp | ||
| $327.41M-0.4% | $328.8M-4.6% | $344.78M+6.6% | $323.55M+0.5% | $321.84M+6.1% | ||
| $593.54M+8.1% | $548.89M+4.9% | $523.36M0.0% | $523.25M+3.2% | $506.81M+3.8% | ||
| $1.01B+4.9% | $966.69M+19.9% | $806.2M+3.1% | $782.08M+2.7% | $761.41M+4.7% | ||
| $80.91M-22.8% | $104.81M-56.5% | $240.92M+1.7% | $236.81M+0.8% | $234.87M+1.8% | ||
| 7.4%-2.4pp | 9.8%-13.2pp | 23%-0.2pp | 23.2%-0.3pp | 23.6%-0.5pp | ||
| $31.88M+0.5% | $31.72M+4.4% | $30.4M+5.8% | $28.74M+3.2% | $27.85M+9.4% | ||
| $2.33M-1.9% | $2.37M+0.9% | $2.35M+0.7% | $2.33M+9.8% | $2.13M+16.6% | ||
| —— | $0-100% | $36.63M-50.0% | $73.26M-33.3% | $109.89M-25.0% | ||
| $115.11M-17.1% | $138.9M-49.2% | $273.67M+2.2% | $267.88M+1.1% | $264.85M+2.6% | ||
| -$260.54M-3.4% | -$252.1M-2,117% | $12.5M-72.7% | $45.72M+27.1% | $35.97M+13.7% | ||
| $375.65M-3.9% | $391M+49.7% | $261.17M+17.6% | $222.16M-2.9% | $228.88M+1.1% | ||
| 34.3%-2.2pp | 36.5%+11.5pp | 24.9%+3.1pp | 21.8%-1.2pp | 23%-0.7pp | ||
| $2.21-3.9% | $2.30+48.4% | $1.55+16.5% | $1.33-2.9% | $1.37+0.7% | ||
| $2.23-3.9% | $2.32+47.8% | $1.57+17.2% | $1.34-2.9% | $1.38+0.7% | ||
| 682M+0.7% | 676.9M+0.5% | 673.4M+0.7% | 668.9M+0.4% | 666.4M+0.2% | ||
| 675.5M+0.6% | 671.8M+0.4% | 669.2M+0.4% | 666.3M+0.3% | 664.1M+0.3% | ||
| $31.88M+0.5% | $31.72M+4.4% | $30.4M+5.8% | $28.74M+3.2% | $27.85M+9.4% | ||
| $913K+4.8% | $871K-2.7% | $895K+0.1% | $894K-1.4% | $907K-1.4% | ||
| —— | $25.17M+5.9% | $23.76M+6.3% | $22.35M+6.7% | $20.93M+7.2% | ||
| -$5.85M-10.6% | -$5.29M-298% | $2.67M+1,140% | $215K+117% | -$1.24M+8.4% | ||
| $4.41M+123% | -$19.27M-124% | $79.9M+22.2% | $65.37M+11.3% | $58.75M-17.3% | ||
| $2.3M-19.4% | $2.86M+42.4% | $2.01M+68.7% | $1.19M+154% | $468K+500% | ||
| -$7.33M-778% | $1.08M+175% | -$1.43M-109% | $16.19M+86.3% | $8.69M+199% | ||
| $2.33M-1.9% | $2.37M+0.9% | $2.35M+0.7% | $2.33M+9.8% | $2.13M+16.6% | ||
| $9.9M+111% | $4.69M+312% | $1.14M+38.8% | $820K— | —— | ||
| $52.28M+4.8% | $49.88M+70.9% | $29.19M+45.7% | $20.03M+162% | $7.64M+11.6% | ||
| $449.23M-9.0% | $493.53M-1.2% | $499.63M+12.7% | $443.14M+12.7% | $393.25M+19.7% | ||
| $1.1B+2.2% | $1.07B+2.3% | $1.05B+2.8% | $1.02B+2.3% | $996.28M+4.0% | ||
| $55.45M+6.4% | $52.14M+5.6% | $49.35M-20.8% | $62.33M-2.1% | $63.68M-5.0% | ||
| $80.91M-22.8% | $104.81M-56.5% | $240.92M+1.7% | $236.81M+0.8% | $234.87M+1.8% | ||
| $92.71M-20.5% | $116.57M-54.3% | $254.97M+1.8% | $250.48M+0.9% | $248.18M+0.6% | ||
| $92.71M-20.5% | $116.57M-54.3% | $254.97M+1.8% | $250.48M+0.9% | $248.18M+0.6% | ||
| 8.5%-2.4pp | 10.9%-13.5pp | 24.3%-0.2pp | 24.6%-0.3pp | 24.9%-0.8pp | ||
| $80.91M-22.8% | $104.81M-56.5% | $240.92M+1.7% | $236.81M+0.8% | $234.87M+1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Acadia Pharmaceuticals's profit margins?
- Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.
- Where does Acadia Pharmaceuticals's income statement data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.